Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 3/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 7/20 | 0.35 |
| ▸ | CCR3 | P51677 | 7/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451108 | 0.89 | HRH1 (0.38) | NR1H2NR1H3FFAR4HRH3HRH1 | |
| SCHEMBL22311115 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3PDK2HRH1CCR3 | |
| SCHEMBL25551636 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3PDK2HRH1CCR3 | |
| SCHEMBL20061096 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3PDK2HRH1CCR3 | |
| SCHEMBL30450973 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3PDK2HRH1CCR3 | |
| SCHEMBL20060947 | 0.87 | NR1H2 (0.62) | NR1H2NR1H3PDK2HRH1CCR3 | |
| SCHEMBL20060951 | 0.86 | HRH3 (0.39) | FFAR4HRH3HRH1CCR3KCNH2 | |
| SCHEMBL20061047 | 0.86 | GPR119 (0.49) | NR1H2NR1H3 | |
| SCHEMBL20061049 | 0.86 | GPR119 (0.49) | NR1H2NR1H3 | |
| SCHEMBL20068553 | 0.86 | GPR119 (0.49) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885PDK2 2381/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885PDK2 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.